These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 20185633)

  • 21. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. The dominant mechanism depends on individual circumstance.
    Mathai ML
    J Appl Physiol (1985); 2010 Dec; 109(6):2011. PubMed ID: 21188826
    [No Abstract]   [Full Text] [Related]  

  • 22. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system.
    Head GA; Burke SL
    J Appl Physiol (1985); 2010 Dec; 109(6):2010. PubMed ID: 21188825
    [No Abstract]   [Full Text] [Related]  

  • 23. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Hung jury?
    Bie P; Damkjaer M
    J Appl Physiol (1985); 2010 Dec; 109(6):2011. PubMed ID: 21188841
    [No Abstract]   [Full Text] [Related]  

  • 24. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. The role of the sympathetic nervous system--influences of sex and aging.
    Charkoudian N; Hart EC; Barnes JN; Joyner MJ
    J Appl Physiol (1985); 2010 Dec; 109(6):2005. PubMed ID: 21188833
    [No Abstract]   [Full Text] [Related]  

  • 25. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system.
    Zhao D
    J Appl Physiol (1985); 2010 Dec; 109(6):2010. PubMed ID: 21188837
    [No Abstract]   [Full Text] [Related]  

  • 26. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Remodeling of central sympathetic circuits precedes the development of hypertension.
    Murphy MN
    J Appl Physiol (1985); 2010 Dec; 109(6):2011-2. PubMed ID: 21188827
    [No Abstract]   [Full Text] [Related]  

  • 27. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system.
    Cowley AW
    J Appl Physiol (1985); 2010 Dec; 109(6):2009-10. PubMed ID: 21188824
    [No Abstract]   [Full Text] [Related]  

  • 28. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. Carotid stimulation studies support a prominent role for the sympathetic nervous system.
    Wehrwein EA
    J Appl Physiol (1985); 2010 Dec; 109(6):2009. PubMed ID: 21188821
    [No Abstract]   [Full Text] [Related]  

  • 29. Comments on Point:Counterpoint: The dominant contributor to systemic hypertension: Chronic activation of the sympathetic nervous system vs. Activation of the intrarenal renin-angiotensin system. The kidney is not always the target in neurogenic hypertension.
    Osborn JW; Fink GD
    J Appl Physiol (1985); 2010 Dec; 109(6):2008. PubMed ID: 21188820
    [No Abstract]   [Full Text] [Related]  

  • 30. [Renal sequelae of sympathetic hyperactivity].
    Watschinger B; Habicht A
    Wien Med Wochenschr; 2004; 154 Spec No 1(1):7-9. PubMed ID: 15346546
    [No Abstract]   [Full Text] [Related]  

  • 31. The importance of sleep blood pressure.
    Morgan TO
    Expert Rev Cardiovasc Ther; 2010 Jun; 8(6):803-9. PubMed ID: 20528638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and clinical investigations in patients with low-renin hypertension.
    Mackenzie IS; Brown MJ
    Clin Exp Nephrol; 2009 Feb; 13(1):1-8. PubMed ID: 18704622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
    Brooks DP; Ruffolo RR
    J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The sympathorenal axis in hypertension and heart failure.
    Goldsmith SR; Sobotka PA; Bart BA
    J Card Fail; 2010 May; 16(5):369-73. PubMed ID: 20447571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Kidney and hypertension].
    Menne J; Fliser D; Haller H
    Herz; 2006 Jun; 31(4):317-21. PubMed ID: 16810471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prospects for pharmacological effects on renin-angiotensin and sympathetic nervous systems in patients with arterial hypertension].
    Chikhladze NM
    Ter Arkh; 2000; 72(12):67-9. PubMed ID: 11201840
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment resistant hypertension and renal sympathetic denervation: drug adherence and the consolidation of blood pressure lowering effects.
    Kjeldsen SE; Os I; Mahfoud F
    EuroIntervention; 2013 May; 9 Suppl R():R7-9. PubMed ID: 23732159
    [No Abstract]   [Full Text] [Related]  

  • 38. [Salt sensitivity in patients with arterial hypertension].
    Babkin AP; Gladkikh VV; Pershukov IV
    Kardiologiia; 2010; 50(9):57-62. PubMed ID: 21118168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Charting new frontiers in interventional medicine.
    Fajadet J
    EuroIntervention; 2013 May; 9 Suppl R():R10-1. PubMed ID: 23732138
    [No Abstract]   [Full Text] [Related]  

  • 40. Bradykinin in the treatment of arterial hypertension: friend or foe?
    Marketou ME; Vardas PE
    Hellenic J Cardiol; 2012 Mar; 53(2):91-4. PubMed ID: 22484773
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.